MediciNova Company Insiders
| MNOV Stock | USD 1.38 0.09 6.98% |
MediciNova's insiders are aggressively selling. The analysis of the overall insider sentiment regarding MediciNova suggests that vertually all insiders are panicking. MediciNova employs about 13 people. The company is managed by 16 executives with a total tenure of roughly 113 years, averaging almost 7.0 years of service per executive, having 0.81 employees per reported executive.
| Yuichi Iwaki CEO President CEO, Director |
| Jeffrey Himawan Chairman Independent Chairman of the Board |
MediciNova's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2022-11-28 | Hideki Nagao | Disposed 6754 @ 2.25 | View | ||
| 2022-11-17 | Hideki Nagao | Disposed 309 @ 2.18 | View |
Monitoring MediciNova's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
MediciNova |
MediciNova Management Team Effectiveness
The company has return on total asset (ROA) of (0.0881) % which means that it has lost $0.0881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1293) %, meaning that it created substantial loss on money invested by shareholders. MediciNova's management efficiency ratios could be used to measure how well MediciNova manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, MediciNova's Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to climb to about 4.8 M in 2024, whereas Other Assets are likely to drop slightly above 101.4 K in 2024.Common Stock Shares Outstanding is likely to drop to about 24.6 M in 2024. Net Loss is likely to drop to about (13.3 M) in 2024
MediciNova Workforce Comparison
MediciNova is regarded second in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 71,914. MediciNova adds roughly 13.0 in number of employees claiming only tiny portion of equities under Health Care industry.
MediciNova Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MediciNova insiders, such as employees or executives, is commonly permitted as long as it does not rely on MediciNova's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, MediciNova insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Masatsune Okajima over two months ago Exercise of in-the-money or at-the-money derivative position by Masatsune Okajima of 8400 shares of MediciNova | ||
Geoffrey OBrien over three months ago Acquisition by Geoffrey OBrien of 84000 shares of MediciNova subject to Rule 16b-3 |
MediciNova Notable Stakeholders
A MediciNova stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MediciNova often face trade-offs trying to please all of them. MediciNova's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MediciNova's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Yuichi Iwaki | President CEO, Director | Profile | |
| Jeffrey Himawan | Independent Chairman of the Board | Profile | |
| Geoffrey OBrien | Vice President IR Contact Officer | Profile | |
| Esther Boom | CFO | Profile | |
| Carla Reyes | CFO | Profile | |
| Ryan Selhorn | CFO | Profile | |
| Yutaka Kobayashi | Director | Profile | |
| Yoshio Ishizaka | Director | Profile | |
| Hideki Nagao | Director | Profile | |
| Masatsune Okajima | Head of Japanese Office and VP | Profile | |
| Jason CPA | CFO Officer | Profile | |
| Kazuko Matsuda | Chief Medical Officer | Profile | |
| Dr MBA | Chief Officer | Profile | |
| MD MPH | Chief Director | Profile | |
| Yuichi MD | President, CoFounder | Profile | |
| John CPA | Controller | Profile |
About MediciNova Management Performance
The success or failure of an entity such as MediciNova often depends on how effective the management is. MediciNova management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MediciNova management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MediciNova management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.17) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.14) | (0.14) |
The data published in MediciNova's official financial statements usually reflect MediciNova's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of MediciNova. For example, before you start analyzing numbers published by MediciNova accountants, it's critical to develop an understanding of what MediciNova's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of MediciNova's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MediciNova's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in MediciNova's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MediciNova. Please utilize our Beneish M Score to check the likelihood of MediciNova's management manipulating its earnings.
MediciNova Workforce Analysis
Traditionally, organizations such as MediciNova use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MediciNova within its industry.MediciNova Manpower Efficiency
Return on MediciNova Manpower
| Revenue Per Employee | 76.9K | |
| Revenue Per Executive | 62.5K | |
| Net Loss Per Employee | 659.3K | |
| Net Loss Per Executive | 535.7K | |
| Working Capital Per Employee | 3.7M | |
| Working Capital Per Executive | 3M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MediciNova. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy MediciNova Stock please use our How to Invest in MediciNova guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for MediciNova Stock analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is MediciNova's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MediciNova. If investors know MediciNova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MediciNova listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.17) | Revenue Per Share 0.02 | Return On Assets (0.09) | Return On Equity (0.13) |
The market value of MediciNova is measured differently than its book value, which is the value of MediciNova that is recorded on the company's balance sheet. Investors also form their own opinion of MediciNova's value that differs from its market value or its book value, called intrinsic value, which is MediciNova's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MediciNova's market value can be influenced by many factors that don't directly affect MediciNova's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MediciNova's value and its price as these two are different measures arrived at by different means. Investors typically determine if MediciNova is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MediciNova's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.